Koschei the immortal and anti-aging drugs

Koschei the immortal and anti-aging drugs

Abstract

In Slavic folklore, Koschei the Immortal was bony, thin and lean. Was his condition caused by severe calorie restriction (CR)? CR deactivates the target of rapamycin pathway and slows down aging. But the life-extending effect of severe CR is limited by starvation. What if Koschei’s anti-aging formula included rapamycin? And was rapamycin (or another rapalog) combined with commonly available drugs such as metformin, aspirin, propranolol, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors.

Facts

  • Calorie restriction deactivates mTOR and increases life span

  • Rapamycin prevents obesity and extends life span

  • In fairy tales, long-lived heroes were lean, slim and bony

Open Questions

  • Were their leanness and longevity due to genetic inhibition of mTOR?

  • Can leanness plus longevity be achieved by rapamycin?

  • How to combine five clinically available anti-aging drugs with calorie restriction?

Koschei the deathless (a villain in Russian, Polish and Ukrainian fairy tales) was immortal, strong, bony and lean (Figure 1). Was it his passion for the young princess Vassilisa, the Beautiful, who rendered him immortal? Did he lose his appetite because of his tragic love? Or was he secretly taking a rapalog such as rapamyin (Sirolimus), Temsirolimus, Everolimus and Deforolimus. And did Koschei benefit from benevolent glucose intolerance? Or, in contrast, was he insulin hypersensitive? Here are some answers and subsequent questions - https://www.nature.com/articles/cddis2014520

When public speak of today’s medicine, accuracy plays one of the most significant roles and human lives are literally dependent on it. Hence, any researches pertaining to medicine are necessary to comply with the highest standards. The issue today is that any outcomes of researches can be published online and used as a reference without being thoroughly checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That helps both readers and authors to validate publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a full publications list with corresponding scores higher than 100 as well as reports discussed previously. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it creates the necessary help to anyone, who has interest in oncology.
Zoya Demidenko
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was released back in 2018 by Oncotarget and completed by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to understand the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Likewise, the article about melanoma, was utilized for citations in various news articles 69 times. In addition, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This research has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a brief overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do get useful scientific facts. Oncotarget is proud to have the chance to share with online customers this highly appreciated and high-quality information, that is trustworthy and reliable.
Misha Blagosklonny

Comments

Post a Comment

Popular posts from this blog

Association of Mycoplasma hominis infection with prostate cancer

Image
Association of Mycoplasma hominis infection with prostate cancer ABSTRACT The origin of chronic inflammation preceding the development of prostate cancer (PCa) remains unknown.  We investigated possible involvement of mycoplasma infection in PCa by screening prostate biopsies from two groups of Russian men undergoing PCa diagnosis.  M. hominis  was detected by standard PCR in 15% of the 125 patients in the first group and by quantitative real-time PCR in 37.4% of the 123 men in the second group. In both groups, stratification of patients according to diagnosis showed that  M. hominis  was present at three times higher frequency in patients with PCa than in those with benign prostatic hyperplasia.   No  M. hominis  was detected in the prostates of 27 men without detectable prostate disease. In addition, PCa-positive men had higher titers of antibodies against  M. hominis  and average PSA levels were higher in  M. hominis -positive men.  These data, together with previous observations li
Read more

Targeting Translation Dependence in Cancer

Image
Targeting Translation Dependence in Cancer ABSTRACT A challenge in cancer therapy is to selectively target activities that are essential for survival of malignant cells while sparing normal cells. Translational control represents a potential anti-neoplastic target because it is exerted by major signaling pathways that are often usurped in cancers. Herein we describe approaches being developed that target eukaryotic initiation factor (eIF) 4F, a heterotrimeric complex that integrates multiple signaling inputs to the translation apparatus.  https://www.oncotarget.com/article/218/ oncotarget  When people discuss today’s medicine, accuracy plays one of the most significant roles and human lives are literally dependent on it. Hereby, any researches related to medicine are necessary to meet the top standards. The issue today is that any recommendations of researches can be shared online and used as a reference without being precisely checked and validated. Mikhail (Misha) Blagosklonny of Onc
Read more

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival

Image
Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival Laboratory models show that the beta-blocker, propranolol, can inhibit norepinephrine-induced breast cancer cell migration. We hypothesised that breast cancer patients receiving beta-blockers for hypertension would show reduced metastasis and improved clinical outcome. Three patient subgroups were identified from the medical records of 466 consecutive female patients (median age 57, range 28-71) with operable breast cancer and follow-up (>10 years). Two subgroups comprised 43 and 49 hypertensive patients treated with beta-blockers or other antihypertensives respectively, prior to cancer diagnosis. 374 patients formed a non-hypertensive control group. Metastasis development, disease free interval, tumour recurrence and hazards risk were statistically compared between groups. Kaplan-Meier plots were used to model survival and DM. Beta-blocker treated patients showed a si
Read more